Unknown PHASE3 INTERVENTIONAL 2-arm NCT05673590

Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase III, Open-label, Randomized, Controlled Clinical Study of Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Previously Failed Platinum-containing Chemotherapy Regimens

Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.

Conditions Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions Docetaxel Injection Utidelone Injection

Updated 5 times since 2023 Last updated: Nov 7, 2023 Started: May 12, 2023 Primary completion: Jun 15, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05673590, this PHASE3 trial focuses on Locally Advanced or Metastatic Non-Small Cell Lung Cancer and remains ongoing. Sponsored by Beijing Biostar Pharmaceuticals Co., Ltd., it has been updated 5 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE3

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Feb 2023 — Dec 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Biostar Pharmaceuticals Co., Ltd.

Data source: Beijing Biostar Pharmaceuticals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China